Trinity Biotech(DE:TRB0)
€63.600.00 (0.00%)
DE:TRB0
Trinity Biotech financials statements
€63.60
At close:0.00 (0.00%)
Trinity Biotech (TRB0) Ratios
0 Followers
Trinity Biotech Ratios
DE:TRB0's free cash flow for Q4 2025 was $-1.54M. For the 2025 fiscal year, DE:TRB0's free cash flow was increased by $11.14K and operating cash flow was $-1.55M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.25 | 1.28 | 2.60 | 2.69 | 0.72 |
| Quick Ratio | 0.12 | 0.68 | 1.27 | 1.39 | 0.43 |
| Cash Ratio | 0.04 | 0.16 | 0.25 | 0.38 | 0.26 |
| Solvency Ratio | -0.20 | -0.22 | -0.27 | -0.41 | 0.03 |
| Operating Cash Flow Ratio | -0.04 | -0.13 | -0.77 | -0.05 | 0.13 |
| Short-Term Operating Cash Flow Coverage | -0.05 | -19.96 | -55.03 | -4.39 | 0.16 |
| Net Current Asset Value | $ -141.25M | $ -97.35M | $ -44.34M | $ -47.61M | $ -46.53M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 1.31 | 0.98 | 1.13 | 0.78 | 0.83 |
| Debt-to-Equity Ratio | -1.92 | -2.86 | -2.82 | -33.18 | -310.84 |
| Debt-to-Capital Ratio | 2.09 | 1.54 | 1.55 | 1.03 | 1.00 |
| Long-Term Debt-to-Capital Ratio | -0.29 | 1.67 | 1.78 | 1.04 | 0.00 |
| Financial Leverage Ratio | -1.46 | -2.94 | -2.48 | -42.33 | -372.71 |
| Debt Service Coverage Ratio | -0.17 | -1.78 | -2.32 | -0.66 | 0.12 |
| Interest Coverage Ratio | -0.87 | -2.21 | -2.67 | -0.62 | 0.55 |
| Debt to Market Cap | 8.65 | 5.57 | 0.67 | 0.35 | 0.56 |
| Interest Debt Per Share | 244.02 | 6.14 | 10.13 | 14.37 | 25.42 |
| Net Debt to EBITDA | -6.21 | -5.65 | -2.64 | -3.93 | 6.92 |
| Profitability Margins | |||||
| Gross Profit Margin | 38.57% | 34.83% | 34.22% | 35.26% | 41.23% |
| EBIT Margin | -54.96% | -30.49% | -45.53% | -30.46% | 9.67% |
| EBITDA Margin | -48.83% | -27.46% | -42.40% | -26.73% | 13.05% |
| Operating Profit Margin | -26.07% | -34.38% | -47.59% | -24.42% | 4.85% |
| Pretax Profit Margin | -84.91% | -49.92% | -64.98% | -70.02% | -2.37% |
| Net Profit Margin | -85.36% | -51.64% | -42.26% | -65.58% | 1.08% |
| Continuous Operations Profit Margin | -85.36% | -50.71% | -64.87% | -69.71% | -2.28% |
| Net Income Per EBT | 100.54% | 103.45% | 65.04% | 93.65% | -45.48% |
| EBT Per EBIT | 325.66% | 145.19% | 136.54% | 286.72% | -48.86% |
| Return on Assets (ROA) | -35.54% | -30.78% | -40.41% | -44.52% | 0.74% |
| Return on Equity (ROE) | 51.92% | 90.36% | 100.29% | 1884.28% | -274.29% |
| Return on Capital Employed (ROCE) | 31.67% | -29.73% | -60.91% | -20.42% | 21.40% |
| Return on Invested Capital (ROIC) | -15.27% | -28.72% | -58.31% | -19.83% | 3.65% |
| Return on Tangible Assets | -77.58% | -61.20% | -55.64% | -72.14% | 1.06% |
| Earnings Yield | -254.37% | -201.14% | -29.19% | -24.55% | 0.59% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.26 | 4.21 | 4.25 | 3.99 | 5.17 |
| Payables Turnover | 2.34 | 5.87 | 9.62 | 8.50 | 8.12 |
| Inventory Turnover | 1.43 | 2.07 | 1.88 | 2.34 | 1.88 |
| Fixed Asset Turnover | 8.26 | 13.32 | 30.04 | 11.00 | 13.71 |
| Asset Turnover | 0.42 | 0.60 | 0.96 | 0.68 | 0.68 |
| Working Capital Turnover Ratio | -0.91 | 3.73 | 2.13 | 81.94 | 5.71 |
| Cash Conversion Cycle | 185.45 | 200.71 | 242.63 | 204.20 | 219.35 |
| Days of Sales Outstanding | 85.71 | 86.60 | 85.94 | 91.39 | 70.66 |
| Days of Inventory Outstanding | 255.49 | 176.29 | 194.63 | 155.76 | 193.67 |
| Days of Payables Outstanding | 155.75 | 62.17 | 37.93 | 42.95 | 44.97 |
| Operating Cycle | 341.20 | 262.88 | 280.57 | 247.15 | 264.33 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -9.58 | -0.23 | -1.51 | -0.14 | 3.17 |
| Free Cash Flow Per Share | -19.63 | -0.79 | -1.61 | -1.02 | 1.09 |
| Dividend Paid and CapEx Coverage Ratio | -0.95 | -0.42 | -14.39 | -0.15 | 1.52 |
| Capital Expenditure Coverage Ratio | -0.95 | -0.42 | -14.39 | -0.15 | 1.52 |
| Operating Cash Flow Coverage Ratio | -0.04 | -0.04 | -0.17 | -0.01 | 0.13 |
| Operating Cash Flow to Sales Ratio | -0.14 | -0.07 | -0.20 | -0.01 | 0.16 |
| Free Cash Flow Yield | -82.70% | -90.20% | -15.02% | -4.13% | 3.04% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.40 | -0.50 | -3.43 | -4.07 | 170.80 |
| Price-to-Sales (P/S) Ratio | 0.34 | 0.26 | 1.45 | 2.67 | 1.84 |
| Price-to-Book (P/B) Ratio | -0.20 | -0.45 | -3.44 | -76.74 | -468.49 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.21 | -1.11 | -6.66 | -24.21 | 32.87 |
| Price-to-Operating Cash Flow Ratio | -2.48 | -3.77 | -7.12 | -181.31 | 11.29 |
| Price-to-Earnings Growth (PEG) Ratio | -0.03 | 0.01 | 0.07 | 0.00 | -1.50 |
| Enterprise Value Multiple | -6.90 | -6.59 | -6.06 | -13.92 | 21.02 |
| Enterprise Value | 147.54M | 111.40M | 146.03M | 232.61M | 222.69M |
| EV to EBITDA | -6.90 | -6.59 | -6.06 | -13.92 | 21.02 |
| EV to Sales | 3.37 | 1.81 | 2.57 | 3.72 | 2.74 |
| EV to Free Cash Flow | -12.14 | -7.81 | -11.81 | -33.72 | 48.98 |
| EV to Operating Cash Flow | -24.88 | -26.58 | -12.64 | -252.56 | 16.82 |
| Tangible Book Value Per Share | -208.28 | -4.82 | -5.25 | -5.55 | -8.68 |
| Shareholders’ Equity Per Share | -116.25 | -1.96 | -3.13 | -0.32 | -0.08 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | -0.02 | 0.00 | 0.00 | 0.04 |
| Revenue Per Share | 70.71 | 3.43 | 7.42 | 9.27 | 19.41 |
| Net Income Per Share | -60.36 | -1.77 | -3.14 | -6.08 | 0.21 |
| Tax Burden | 1.01 | 1.03 | 0.65 | 0.94 | -0.45 |
| Interest Burden | 1.54 | 1.64 | 1.43 | 2.30 | -0.25 |
| Research & Development to Revenue | 0.08 | 0.07 | 0.08 | 0.07 | 0.06 |
| SG&A to Revenue | 0.56 | 0.47 | 0.00 | 0.00 | 0.30 |
| Stock-Based Compensation to Revenue | 0.01 | 0.02 | 0.04 | 0.03 | 0.01 |
| Income Quality | 0.16 | 0.13 | 0.48 | 0.02 | 15.13 |
Currency in USD
